Clostridium difficile-associated diarrhea from a general hospital in Argentina

被引:27
|
作者
Legaria, MC [1 ]
Lumelsky, G [1 ]
Rosetti, S [1 ]
机构
[1] Hosp Gen Agudos E Tornu, Unidad Microbiol, RA-3002 Buenos Aires, DF, Argentina
关键词
Clostridium difficile; antibiotic-associated diarrhea; DIAGNOSIS; EPIDEMIOLOGY;
D O I
10.1016/S1075-9964(03)00088-X
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Clostridium difficile is responsible for 15-25% of all cases of antibiotic associated diarrhea. The incidence of infection with this organism is increasing in hospitals worldwide, consequent to the widespread use of broad-spectrum antibiotics. Although the clinical and financial impact of nosocomial C difficile infection is believed to be significant, only limited information is available on the importance of C difficile as a cause of diarrhea in Argentina. The aim of the study was to evaluate the impact and diagnosis methods of MAD from symptomatic patients in a general hospital from Argentina. Consecutive diarrheal stool samples from symptomatic patients from a General Hospital in Argentina were screened for toxigenic C. difficile between April 2000 and April 2001. Toxins were detected in stools by the Premier Cytoclone A+ B EIA. Each specimen was examined for toxigenic C. difficile strains by culture. From 104 specimens, 40 (38.5%) [32 of 87 patients (36.8%)] were positive and 64 (61.5%) [55 of 87 patients (63.2%)] were negative by stool toxin assay and/or toxigenic culture. In I I of 40 positives samples C. difficile toxins were detected only by toxigenic culture. Five (15.6%) patients presented with symptomatic recurrences. Toxin-negative strains were not isolated. This data indicates that the high prevalence of toxigenic strains of C. difficile is of concern in routine diagnostic testing for C. difficile toxins in our study population. Detection of toxins in stools by EIA, coupled with testing strains for toxigenicity only in those cases in which direct toxin assay produces negative results, may be a satisfactory strategy. MAD is an emerging nosocomial problem in our hospital. It will be necessary to evaluate the epidemiology and measures to control nosocomial spread. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:113 / 116
页数:4
相关论文
共 50 条
  • [21] Clostridium difficile-associated diarrhea with hematochezia is associated with ulcer formation
    Morimoto, Yasutaka
    Nomura, Kenichi
    Tsutsumi, Yasuhiko
    Ohshiro, Muneo
    Fujimoto, Yoshiko
    Shimizu, Daisuke
    Wakabayashi, Naoki
    Konishi, Hideyuki
    Mitsufuji, Shoji
    Matsumoto, Yosuke
    Taniwaki, Masafumi
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2008, 43 (08) : 967 - 970
  • [22] Do Probiotics Prevent Clostridium difficile-Associated Diarrhea?
    Al Sharaby, Afrah
    Abugoukh, Tahani M.
    Ahmed, Wefag
    Ahmed, Samah
    Elshaikh, Abeer O.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [23] Fecal Microbiota Transplantation for Clostridium difficile-Associated Diarrhea
    Cohen, Nathaniel A.
    Ben Ami, Ronen
    Guzner-Gur, Hanan
    Santo, Moshe E.
    Halpern, Zamir
    Maharshak, Nitsan
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2015, 17 (08): : 510 - 514
  • [24] Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease
    Bossuyt, Peter
    Verhaegen, Jan
    Van Assche, Gert
    RutgeertS, Paul
    Vermeire, Severine
    JOURNAL OF CROHNS & COLITIS, 2009, 3 (01): : 4 - 7
  • [25] Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
    Goldenberg, Joshua Z.
    Ma, Stephanie S. Y.
    Saxton, Jane D.
    Martzen, Mark R.
    Vandvik, Per O.
    Thorlund, Kristian
    Guyatt, Gordon H.
    Johnston, Bradley C.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (05):
  • [26] Molecular analysis of relapses or reinfections of Clostridium difficile-associated diarrhea
    Sisto, Francesca
    Scaltrito, Maria Maddalena
    Zago, Miriam
    Bonomi, Arianna
    Cocce, Valentina
    Frugoni, Sergio
    NEW MICROBIOLOGICA, 2011, 34 (04): : 399 - 402
  • [27] Safety and efficacy of fidaxomicin in the treatment of Clostridium difficile-associated diarrhea
    Golan, Yoav
    Epstein, Lauren
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2012, 5 (06): : 395 - 402
  • [28] Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding
    Bliss, DZ
    Johnson, S
    Savik, K
    Clabots, CR
    Willard, K
    Gerding, DN
    ANNALS OF INTERNAL MEDICINE, 1998, 129 (12) : 1012 - +
  • [29] Cost analysis of hospitalized Clostridium difficile-associated diarrhea (CDAD)
    Huebner, Claudia
    Huebner, Nils-Olaf
    Muhr, Michaela
    Claus, Franziska
    Leesch, Henning
    Kramer, Axel
    Flessa, Steffen
    GMS HYGIENE AND INFECTION CONTROL, 2015, 10
  • [30] Cost Analysis of Hospitalized Clostridium Difficile-Associated Diarrhea (CDAD)
    Huebner, C.
    Huebner, N-O
    Muhr, M.
    Claus, F.
    Leesch, H.
    Kramer, A.
    Flessa, S.
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2013, 18 (02): : 80 - 85